Immunoreactivity assay for labeled anti-melanoma monoclonal antibodies

P. L. Beaumier, D. Neuzil, H. M. Yang, E. A. Noll, R. Kishore, J. F. Eary, K. A. Krohn, W. B. Nelp, K. E. Hellström, I. Hellström

Research output: Contribution to journalArticle

43 Scopus citations

Abstract

A convenient, rapid, and reproducible assay was developed to evaluate the immunoreactivity of radiolabeled monoclonal antibodies against three different human melanoma-associated antigens, p97, a proteoglycan and a GD3 ganglioside. A cloned melanoma cell line (M 2669 CL13) was selected as the target and, when fixed with paraformaldehyde, showed binding as good as or better than that obtained with live cells for the three antigens. Fixed cells retained good binding properties stored at 4°C for over 6 mo. This assay has general applicability to other antigen-antibody systems for testing chemically modified monoclonal antibodies or fragments during the development of a radiopharmaceutical or as a routine quality control measure for clinical agents.

Original languageEnglish (US)
Pages (from-to)824-828
Number of pages5
JournalJournal of Nuclear Medicine
Volume27
Issue number6
StatePublished - Dec 1 1986

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Immunoreactivity assay for labeled anti-melanoma monoclonal antibodies'. Together they form a unique fingerprint.

  • Cite this

    Beaumier, P. L., Neuzil, D., Yang, H. M., Noll, E. A., Kishore, R., Eary, J. F., Krohn, K. A., Nelp, W. B., Hellström, K. E., & Hellström, I. (1986). Immunoreactivity assay for labeled anti-melanoma monoclonal antibodies. Journal of Nuclear Medicine, 27(6), 824-828.